Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Capital Expenditures: 2015-2025

Historic Capital Expenditures for Sunshine Biopharma (SBFM) over the last 5 years, with Sep 2025 value amounting to $8,040.

  • Sunshine Biopharma's Capital Expenditures fell 98.44% to $8,040 in Q3 2025 from the same period last year, while for Sep 2025 it was $278,130, marking a year-over-year decrease of 76.27%. This contributed to the annual value of $1.7 million for FY2024, which is 1914.63% up from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's Capital Expenditures is $8,040, which was down 94.97% from $160,000 recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Capital Expenditures ranged from a high of $974,513 in Q2 2024 and a low of -$382,363 during Q4 2023.
  • Over the past 3 years, Sunshine Biopharma's median Capital Expenditures value was $62,937 (recorded in 2024), while the average stood at $162,206.
  • Its Capital Expenditures has fluctuated over the past 5 years, first tumbled by 297.11% in 2023, then spiked by 5,266.46% in 2024.
  • Quarterly analysis of 4 years shows Sunshine Biopharma's Capital Expenditures stood at $193,982 in 2022, then plummeted by 297.11% to -$382,363 in 2023, then surged by 126.83% to $102,600 in 2024, then crashed by 98.44% to $8,040 in 2025.
  • Its Capital Expenditures was $8,040 in Q3 2025, compared to $160,000 in Q2 2025 and $7,490 in Q1 2025.